Previous 10 | Next 10 |
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will partic...
Patient in 520 mg/m 2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m 2 cohort achieved stable disease WILMETTE, Ill., June 01, 2023 (...
2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...
2023-05-11 10:03:26 ET Monopar Therapeutics press release ( NASDAQ: MNPR ): Q1 GAAP EPS of -$0.19 beats by $0.03 . Cash, cash equivalents and shortterm investments as of March 31, 2023, were $11.7 million. For further details see: Monopar Therapeutics G...
WILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinicalstage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today anno...
2023-03-28 13:10:56 ET Gainers: Biomea Fusion ( BMEA ) +73% . Oscar Health ( OSCR ) +72% . Viking Therapeutics ( VKTX ) +63% . Pyxis Oncology ( PYXS ) +46% . Bird Global ( BRDS ) +44% . NaaS Technology ( NAAS ) +26% ....
2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
2023-03-28 08:31:04 ET Monopar Therapeutics MNPR -50% as Validive program gets axed after trial failure . WiSA Technologies WISA -28% after proposes securities offering . OncoSec Medical ( ONCS ) -25% . Allarity Therapeutics ALLR -18% amid enr...
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson...
2023-03-28 05:57:36 ET Monopar Therapeutics' ( NASDAQ: MNPR ) is discontinuing the active development of Validive after the drug did not meet the required efficacy to prevent severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) in a phase 2b/3 trial ca...
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging...
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...